| 摘要 |
The disclosure relates to pentafluorosulfanyl benzoylguanidines of formula (I), in which R1 to R4 correspond to meanings given in the specification. These pentafluorosulfanyl benzoylguanidines are suitable for use as anti-arrhythmic medicaments comprising cardio-protective components for the prophylaxis and treatment of infarcts, in addition to the treatment of angina pectoris. These compounds also preventatively inhibit the pathophysiological events that occur during ischaemically induced traumas, in particular during the triggering of ischaemically induced cardiac arrhythmia.
|
